Insulet Corp (PODD)

$306.21 -4.69 (-1.51%)
Market Cap 21.65B
Revenue (ttm) 2.07B
Net Income (ttm) 418.30M
EPS (ttm) N/A
PE Ratio 83.74
Forward PE 69.97
Profit Margin 20.19%
Debt to Equity Ratio 1.27
Volume 383,707
Avg Vol 854,586
Day's Range N/A - N/A
Shares Out 70.38M
Stochastic %K 74%
Beta 1.37
Analysts Strong Sell
Price Target $341.05

Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system...

Industry: Medical Devices
Sector: Healthcare
Phone: 978 600 7000
Address:
100 Nagog Park, Acton, United States
AdrianDittmann
AdrianDittmann Jun. 24 at 5:29 PM
$SANA $TNDM $PODD $MDT $SPY Have you seen Sana Biotech's new treatment, they were able to transfer modified islet cells that can evade the immune system. I think we are finally there! What do you guys think?
2 · Reply
AdrianDittmann
AdrianDittmann Jun. 24 at 2:18 AM
$SANA $TNDM $PODD $MDT $SPY okay do the liver next, so I can drink more https://www.globenewswire.com/news-release/2025/06/23/3103540/0/en/sana-biotechnology-announces-positive-six-month-clinical-results-from-type-1-diabetes-study-of-islet-cell-transplantation-without-immunosuppression.html
1 · Reply
Estimize
Estimize Jun. 23 at 1:03 PM
Wall St is expecting 0.92 EPS for $PODD Q2 [Reporting 08/07 AMC] http://www.estimize.com/intro/podd?chart=historical&metric_name=eps&utm_co
0 · Reply
CelestialIronMan
CelestialIronMan Jun. 19 at 5:39 PM
$SANA There is no way $LLY $NVO $DXCM $PODD are going to allow us to disrupt T1D treatments out of existence without participation. Once again ask your favorite AI what the HIP platform can be applied too! If we have to actually throw the possibilities of cures out in the public domain to force big pharma to partner and license so be it. But there is no way the company can make it through clinical trials to approval in its current form for anything. Go look up the process, typically 1000 patients over years, with some exceptions for gene therapies, rare diseases, the number of beneficiaries and efficacy can speed it up. We’d be bankrupt, bought off the scrap heap. Better to offer HIP, a working MSCB and targeted delivery tech, all of which we have or are developing than to actually make cures and incur the wrath of the big pharma machinery!
1 · Reply
IN0V8
IN0V8 Jun. 16 at 8:45 PM
$PODD Buy Truist Securities initiates coverage with buy rating Truist Securities initiates coverage with price target $365
0 · Reply
JarvisFlow
JarvisFlow Jun. 16 at 4:08 PM
Truist Securities has adjusted their stance on Insulet ( $PODD ), setting the rating to Buy with a target price of 365.
0 · Reply
zoey1970
zoey1970 Jun. 13 at 3:23 PM
$DXCM $SENS $PODD $ARM $TSM
0 · Reply
ZacksResearch
ZacksResearch Jun. 11 at 3:41 PM
$PODD has risen 55.5% over the past year — is Insulet's growth sustainable? 🚀 Omnipod 5's expansion is a game changer, driving strong adoption with new customer starts, especially in the Type 2 diabetes market. However, macroeconomic challenges and fierce competition could cloud future growth prospects. Opportunity assessment here 👉 https://www.zacks.com/commentary/2494363/heres-why-you-should-retain-podd-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2494363-body&ADID=SYND_STOCKTWITS_TWEET_2_2494363_BODY
0 · Reply
ZacksResearch
ZacksResearch Jun. 11 at 1:44 PM
$PODD gaining steam — here's why it deserves a spot in your portfolio 📈 Omnipod 5 is seeing strong momentum from global expansion and growing adoption among Type 2 users, even with economic and competitive pressures in play. Full breakdown here 👉 https://www.zacks.com/stock/news/2494363/heres-why-you-should-retain-podd-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2494363-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2494363_TEASER
0 · Reply
CelestialIronMan
CelestialIronMan Jun. 9 at 2:34 PM
$SANA I hate cross posting, but I’d love feedback on SANA from you guys over in $DXCM $PODD Nobody wants to hear about threats to their stocks but in this case you all should start looking at SANA. I talk a lot of shit, get in a lot of spats, have a lot of attempts to be funny, I shit on shorts! Every once in a while I help shepherd people to AMD back in 2017, NVTS, BCRX, HOOD, BITCOIN,PLTR through various accounts through the years. I think SANA is another winner, not here for followers or subscriptions. Check it out and comment we need more educated eyes over on our SANA thread here! The science is real https://wsw.com/webcast/jeff319/sana/1837256?mobile=True Wall Street Webcasting - Sana Biotechnology Commentary https://www.zerohedge.com/news/2025-05-19/end-diabetes-industry The End Of The T1 Diabetes Industry? | ZeroHedge
1 · Reply
Latest News on PODD
Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions

Jun 19, 2025, 6:00 AM EDT - 6 days ago

Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions

20 stocks bucking bad trends on Wall Street — what might be next for them?

Jun 10, 2025, 10:53 AM EDT - 15 days ago

20 stocks bucking bad trends on Wall Street — what might be next for them?

AMT ANET AVGO BSX TRMB BAC C

Insulet's Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users

Jun 10, 2025, 8:30 AM EDT - 15 days ago

Insulet's Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users

20 stocks of companies that have improved profit margins and are expected to grow quickly

Jun 9, 2025, 9:28 AM EDT - 16 days ago

20 stocks of companies that have improved profit margins and are expected to grow quickly

AMD AVGO CSGP DASH ENPH FICO FTNT

Insulet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 23, 2025, 6:01 AM EDT - 4 weeks ago

Insulet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Outlier Money Flows Lift Insulet

May 14, 2025, 7:20 AM EDT - 6 weeks ago

Outlier Money Flows Lift Insulet

Insulet Announces Publication of 2024 Sustainability Report

May 13, 2025, 6:00 AM EDT - 6 weeks ago

Insulet Announces Publication of 2024 Sustainability Report

20 stocks of companies showing excellent earnings-season trends even as the economy cools

May 12, 2025, 11:18 AM EDT - 6 weeks ago

20 stocks of companies showing excellent earnings-season trends even as the economy cools

AMD APH CF CTRA DVN ENPH EQT

S&P 500 Gains & Losses Today: Index Pulls Back Early Climb Amid Anticipation of Trade Talks

May 9, 2025, 6:31 PM EDT - 6 weeks ago

S&P 500 Gains & Losses Today: Index Pulls Back Early Climb Amid Anticipation of Trade Talks

Top Stock Movers Now: Tesla, Monster Beverage, Insulet, and More

May 9, 2025, 12:31 PM EDT - 6 weeks ago

Top Stock Movers Now: Tesla, Monster Beverage, Insulet, and More

MNST TSLA

Insulet Posts Strong Q1 Results, Raises Forecasts On Momentum In US And Abroad

May 9, 2025, 11:05 AM EDT - 6 weeks ago

Insulet Posts Strong Q1 Results, Raises Forecasts On Momentum In US And Abroad

Insulet Is the Top S&P 500 Performer Today. Here's Why.

May 9, 2025, 10:11 AM EDT - 6 weeks ago

Insulet Is the Top S&P 500 Performer Today. Here's Why.

Insulet Corporation (PODD) Q1 2025 Earnings Call Transcript

May 8, 2025, 10:35 PM EDT - 6 weeks ago

Insulet Corporation (PODD) Q1 2025 Earnings Call Transcript

Insulet beats quarterly profit estimates on insulin pump demand

May 8, 2025, 4:28 PM EDT - 6 weeks ago

Insulet beats quarterly profit estimates on insulin pump demand

Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency1)

May 8, 2025, 4:01 PM EDT - 6 weeks ago

Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency1)

Insulet Names New CEO, Expects to Top Revenue Projections

Apr 28, 2025, 10:26 AM EDT - 2 months ago

Insulet Names New CEO, Expects to Top Revenue Projections

Insulet Appoints Ashley McEvoy President and CEO

Apr 28, 2025, 6:00 AM EDT - 2 months ago

Insulet Appoints Ashley McEvoy President and CEO

Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025

Apr 3, 2025, 6:00 AM EDT - 2 months ago

Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025

Insulet's RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections

Mar 19, 2025, 4:01 PM EDT - 3 months ago

Insulet's RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections

Insulet Announces Pricing of Senior Notes Due 2033

Mar 18, 2025, 4:32 PM EDT - 3 months ago

Insulet Announces Pricing of Senior Notes Due 2033

Insulet Announces Proposed Financing Transactions

Mar 18, 2025, 7:35 AM EDT - 3 months ago

Insulet Announces Proposed Financing Transactions

Insulet Leans Bullish (Technical Analysis)

Mar 17, 2025, 11:53 PM EDT - 3 months ago

Insulet Leans Bullish (Technical Analysis)

Insulet to Host Investor Day on June 5, 2025

Mar 11, 2025, 6:00 AM EDT - 3 months ago

Insulet to Host Investor Day on June 5, 2025

Insulet Sales Keep Rising

Feb 26, 2025, 8:04 AM EST - 4 months ago

Insulet Sales Keep Rising

Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst

Feb 21, 2025, 1:28 PM EST - 4 months ago

Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst

Insulet Corporation (PODD) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 11:37 PM EST - 4 months ago

Insulet Corporation (PODD) Q4 2024 Earnings Call Transcript

Insulet Reports Full Year 2024 Revenue Increase of 22% and Fourth Quarter 2024 Revenue Increase of 17% Year-Over-Year

Feb 20, 2025, 4:01 PM EST - 4 months ago

Insulet Reports Full Year 2024 Revenue Increase of 22% and Fourth Quarter 2024 Revenue Increase of 17% Year-Over-Year

Insulet Launches Revolutionary Omnipod® 5 in Five More Countries in Europe

Jan 13, 2025, 4:01 PM EST - 5 months ago

Insulet Launches Revolutionary Omnipod® 5 in Five More Countries in Europe

Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

Jan 10, 2025, 6:00 AM EST - 5 months ago

Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

Heavy Interest in Insulet's Insulin Delivery Device

Dec 27, 2024, 3:47 PM EST - 6 months ago

Heavy Interest in Insulet's Insulin Delivery Device

Insulet wins $452 mln US verdict against EOFlow in insulin pump secrets case

Dec 5, 2024, 11:05 AM EST - 7 months ago

Insulet wins $452 mln US verdict against EOFlow in insulin pump secrets case

Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court

Dec 4, 2024, 4:28 PM EST - 7 months ago

Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court

Insulet Corporation: Significant Opportunities, Significant Threats - I'm On The Sidelines

Nov 20, 2024, 6:26 PM EST - 7 months ago

Insulet Corporation: Significant Opportunities, Significant Threats - I'm On The Sidelines

Insulet Announces Omnipod® 5 System is Now Compatible with Abbott's FreeStyle Libre 2 Plus Sensor in the U.S.

Nov 20, 2024, 8:30 AM EST - 7 months ago

Insulet Announces Omnipod® 5 System is Now Compatible with Abbott's FreeStyle Libre 2 Plus Sensor in the U.S.

Insulet to Present at Upcoming Investor Conferences

Nov 15, 2024, 6:00 AM EST - 7 months ago

Insulet to Present at Upcoming Investor Conferences

Insulet CEO on earnings, GLP-1 and election impact

Nov 11, 2024, 4:59 PM EST - 8 months ago

Insulet CEO on earnings, GLP-1 and election impact

Buy, Sell, Or Hold Insulet (PODD) Stock?

Nov 11, 2024, 9:42 AM EST - 8 months ago

Buy, Sell, Or Hold Insulet (PODD) Stock?

Top 4 Health Care Stocks That May Plunge This Quarter

Nov 11, 2024, 6:18 AM EST - 8 months ago

Top 4 Health Care Stocks That May Plunge This Quarter

AIRS NUVB QDEL

Insulet Corporation (PODD) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 10:54 PM EST - 8 months ago

Insulet Corporation (PODD) Q3 2024 Earnings Call Transcript

Insulet raises annual revenue forecast on strong demand for insulin pumps

Nov 7, 2024, 5:44 PM EST - 8 months ago

Insulet raises annual revenue forecast on strong demand for insulin pumps

Insulet Reports Third Quarter 2024 Revenue Increase of 26% Year-Over-Year (25% Constant Currency1)

Nov 7, 2024, 4:01 PM EST - 8 months ago

Insulet Reports Third Quarter 2024 Revenue Increase of 26% Year-Over-Year (25% Constant Currency1)

Insulet Announces Array of Activities to Support National Diabetes Awareness Month and World Diabetes Day in November

Nov 1, 2024, 6:00 AM EDT - 8 months ago

Insulet Announces Array of Activities to Support National Diabetes Awareness Month and World Diabetes Day in November

Omnipod® 5 App for iPhone® Now Fully Available in the United States

Oct 29, 2024, 4:01 PM EDT - 8 months ago

Omnipod® 5 App for iPhone® Now Fully Available in the United States

National Campaign Launches to Combat Diabetes Stigma Using Comedy

Oct 10, 2024, 9:00 AM EDT - 9 months ago

National Campaign Launches to Combat Diabetes Stigma Using Comedy

Insulet to Announce Third Quarter 2024 Financial Results on November 7, 2024

Sep 30, 2024, 6:00 AM EDT - 9 months ago

Insulet to Announce Third Quarter 2024 Financial Results on November 7, 2024

Upstart, Insulet And 2 Other Stocks Executives Are Selling

Sep 12, 2024, 7:44 AM EDT - 10 months ago

Upstart, Insulet And 2 Other Stocks Executives Are Selling

UPST INTU Z

What Helped Insulet Stock Gain 10% This Week?

Aug 30, 2024, 9:00 AM EDT - 10 months ago

What Helped Insulet Stock Gain 10% This Week?

S&P 500 Gains and Losses Today: Medical Device Makers ResMed, Insulet Lead Index

Aug 27, 2024, 6:35 PM EDT - 10 months ago

S&P 500 Gains and Losses Today: Medical Device Makers ResMed, Insulet Lead Index

RMD

This Healthcare Stock Is the Best Performer in the S&P 500 Tuesday

Aug 27, 2024, 11:32 AM EDT - 10 months ago

This Healthcare Stock Is the Best Performer in the S&P 500 Tuesday

Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes

Aug 26, 2024, 4:20 PM EDT - 10 months ago

Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes

AdrianDittmann
AdrianDittmann Jun. 24 at 5:29 PM
$SANA $TNDM $PODD $MDT $SPY Have you seen Sana Biotech's new treatment, they were able to transfer modified islet cells that can evade the immune system. I think we are finally there! What do you guys think?
2 · Reply
AdrianDittmann
AdrianDittmann Jun. 24 at 2:18 AM
$SANA $TNDM $PODD $MDT $SPY okay do the liver next, so I can drink more https://www.globenewswire.com/news-release/2025/06/23/3103540/0/en/sana-biotechnology-announces-positive-six-month-clinical-results-from-type-1-diabetes-study-of-islet-cell-transplantation-without-immunosuppression.html
1 · Reply
Estimize
Estimize Jun. 23 at 1:03 PM
Wall St is expecting 0.92 EPS for $PODD Q2 [Reporting 08/07 AMC] http://www.estimize.com/intro/podd?chart=historical&metric_name=eps&utm_co
0 · Reply
CelestialIronMan
CelestialIronMan Jun. 19 at 5:39 PM
$SANA There is no way $LLY $NVO $DXCM $PODD are going to allow us to disrupt T1D treatments out of existence without participation. Once again ask your favorite AI what the HIP platform can be applied too! If we have to actually throw the possibilities of cures out in the public domain to force big pharma to partner and license so be it. But there is no way the company can make it through clinical trials to approval in its current form for anything. Go look up the process, typically 1000 patients over years, with some exceptions for gene therapies, rare diseases, the number of beneficiaries and efficacy can speed it up. We’d be bankrupt, bought off the scrap heap. Better to offer HIP, a working MSCB and targeted delivery tech, all of which we have or are developing than to actually make cures and incur the wrath of the big pharma machinery!
1 · Reply
IN0V8
IN0V8 Jun. 16 at 8:45 PM
$PODD Buy Truist Securities initiates coverage with buy rating Truist Securities initiates coverage with price target $365
0 · Reply
JarvisFlow
JarvisFlow Jun. 16 at 4:08 PM
Truist Securities has adjusted their stance on Insulet ( $PODD ), setting the rating to Buy with a target price of 365.
0 · Reply
zoey1970
zoey1970 Jun. 13 at 3:23 PM
$DXCM $SENS $PODD $ARM $TSM
0 · Reply
ZacksResearch
ZacksResearch Jun. 11 at 3:41 PM
$PODD has risen 55.5% over the past year — is Insulet's growth sustainable? 🚀 Omnipod 5's expansion is a game changer, driving strong adoption with new customer starts, especially in the Type 2 diabetes market. However, macroeconomic challenges and fierce competition could cloud future growth prospects. Opportunity assessment here 👉 https://www.zacks.com/commentary/2494363/heres-why-you-should-retain-podd-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2494363-body&ADID=SYND_STOCKTWITS_TWEET_2_2494363_BODY
0 · Reply
ZacksResearch
ZacksResearch Jun. 11 at 1:44 PM
$PODD gaining steam — here's why it deserves a spot in your portfolio 📈 Omnipod 5 is seeing strong momentum from global expansion and growing adoption among Type 2 users, even with economic and competitive pressures in play. Full breakdown here 👉 https://www.zacks.com/stock/news/2494363/heres-why-you-should-retain-podd-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2494363-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2494363_TEASER
0 · Reply
CelestialIronMan
CelestialIronMan Jun. 9 at 2:34 PM
$SANA I hate cross posting, but I’d love feedback on SANA from you guys over in $DXCM $PODD Nobody wants to hear about threats to their stocks but in this case you all should start looking at SANA. I talk a lot of shit, get in a lot of spats, have a lot of attempts to be funny, I shit on shorts! Every once in a while I help shepherd people to AMD back in 2017, NVTS, BCRX, HOOD, BITCOIN,PLTR through various accounts through the years. I think SANA is another winner, not here for followers or subscriptions. Check it out and comment we need more educated eyes over on our SANA thread here! The science is real https://wsw.com/webcast/jeff319/sana/1837256?mobile=True Wall Street Webcasting - Sana Biotechnology Commentary https://www.zerohedge.com/news/2025-05-19/end-diabetes-industry The End Of The T1 Diabetes Industry? | ZeroHedge
1 · Reply
trowley0001
trowley0001 Jun. 6 at 12:27 AM
$PODD nah. Keep shorting
1 · Reply
1trendingup
1trendingup Jun. 2 at 6:14 PM
$BBNX lol been loading since low 10’s. Watch out $PODD we’re coming for you
0 · Reply
topstockalerts
topstockalerts May. 30 at 4:26 PM
$PODD let it consolidate.. 😴😴
0 · Reply
JarvisFlow
JarvisFlow May. 30 at 3:52 PM
Goldman Sachs updates rating for Insulet ( $PODD ) to Buy.
0 · Reply
JInvestTrade
JInvestTrade May. 30 at 4:22 AM
Another patient great experience with $SENS eversense 365. $DXCM, $ABT,$PODD https://youtu.be/tml8KR1sFoY
0 · Reply
JInvestTrade
JInvestTrade May. 30 at 4:10 AM
$SENS,$DXCM,$ABT,$PODD https://www.linkedin.com/posts/ascensia-diabetes-care_eversense365-eversensecgm-medtech-activity-7326244519954259968-zGLX?utm_source=share&utm_medium=member_ios&rcm=ACoAACZifW0B2JqOqHkWvrhyPzzcI0ENdA47TYM
0 · Reply
DonCorleone77
DonCorleone77 May. 30 at 1:14 AM
$PODD Insulet initiated with a Buy at Goldman Sachs Goldman Sachs initiated coverage of Insulet with a Buy rating and $380 price target as part of a broader research note launching coverage on Diabetes Medical Technology. Diabetes technology is poised to sustain double-digit growth, and Insulet stands to benefit from accelerating adoption of patch pump technology with the company being the only participant in the category today, the analyst tells investors in a research note. The company's pipeline also offers the potential to further strengthen its relative position, while its sustained top-line growth should support outsized adjusted EBITDA results, Goldman Sachs added.
0 · Reply
jheerdink
jheerdink May. 28 at 9:25 PM
$MODD Please View our latest Tribe event video “Making Diabetes Management Simpler: The New Era of Insulin Therapy” Meet the CEO of Modular Medical $MODD and learn about MODD-1 and more https://youtu.be/7Y5eQv4QMyw?si=_iThdx8os69vWOcs #InsulinPumps Represent the gold standard in glycemic control $PODD $MDT $BBNX
0 · Reply
JarvisFlow
JarvisFlow May. 27 at 3:25 PM
Raymond James has updated their rating for Insulet ( $PODD ) to Outperform with a price target of 360.
0 · Reply
ZacksResearch
ZacksResearch May. 26 at 1:20 PM
$PODD up 78.5% in a year — driven by Omnipod 5 and strategic moves 🚀 📈 Strong momentum with FDA-cleared, fully disposable AID system 🌍 Strategic market expansions into Australia, Belgium, Canada, and Switzerland 💡 Omnipod Discover platform enhances patient engagement Opportunity assessment here 👉 https://www.zacks.com/commentary/2477015/insulet-gains-785-in-a-year-whats-driving-the-stock?cid=sm-stocktwits-2-2477015-body&ADID=SYND_STOCKTWITS_TWEET_2_2477015_BODY
0 · Reply
ZacksResearch
ZacksResearch May. 26 at 11:59 AM
$PODD's shares rise on the back of Omnipod 5's growth, global expansion, and strong Q1 2025 gains despite rising operating costs and macro headwinds. Read more: https://www.zacks.com/stock/news/2477015/insulet-gains-785-in-a-year-whats-driving-the-stock?cid=sm-stocktwits-2-2477015-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2477015_TEASER
0 · Reply
DonCorleone77
DonCorleone77 May. 16 at 11:25 AM
$PODD Insulet price target raised to $375 from $355 at Bernstein Bernstein raised the firm's price target on Insulet to $375 from $355 and keeps an Outperform rating on the shares. The firm notes that against a backdrop of accelerating pump market growth, Insulet has a strong moat around the winning form factor, and Omnipod 5 is the clear winner in the growing T2D market.
0 · Reply